Katana VentraIP

Wellcome Trust

The Wellcome Trust is a charitable foundation focused on health research based in London, United Kingdom. It was established in 1936 with legacies from the pharmaceutical magnate Henry Wellcome (founder of Burroughs Wellcome, one of the predecessors of GSK plc) to fund research to improve human and animal health. The aim of the Trust is to "support science to solve the urgent health challenges facing everyone." It had a financial endowment of £29.1 billion in 2020,[4] making it the fourth wealthiest charitable foundation in the world. In 2012, the Wellcome Trust was described by the Financial Times as the United Kingdom's largest provider of non-governmental funding for scientific research, and one of the largest providers in the world.[6] According to their annual report, the Wellcome Trust spent GBP £1.1 billion on charitable activities across their 2019/2020 financial year.[7] According to the OECD, the Wellcome Trust's financing for 2019 development increased by 22% to US$327 million.[8]

Founded

1936 (1936)

210183

Biomedical Research

London, NW1
United Kingdom

United Kingdom and overseas

£11 billion (1936–2015)[3]

£25.9 billion[4]

2,057[5]

History[edit]

The trust was established to administer the fortune of the American-born British pharmaceutical magnate Sir Henry Wellcome.[10] Its income was derived from what was originally called Burroughs Wellcome, later renamed in the UK as the Wellcome Foundation Ltd.[11] In 1986, the trust sold 25% of Wellcome plc stock to the public. Overseen by incoming Director of Finance Ian Macgregor, this marked the beginning of a period of financial growth that saw the trust's value increase by almost £14 billion in 14 years, as their interests moved beyond the bounds of the pharmaceutical industry.[12]


In 1995, the trust divested itself of any interest in pharmaceuticals by selling all remaining stock to Glaxo plc, the company's historic British rival, creating GlaxoWellcome plc. In 2000, the Wellcome name disappeared from the drug business altogether when GlaxoWellcome merged with SmithKline Beecham, to form GlaxoSmithKline plc.[13]

(ALSPAC), a cohort study of children born in England during 1991 and 1992.

Avon Longitudinal Study of Parents and Children

The at the Wellcome Trust Sanger Institute.

Cancer Genome Project

The , the UK's national synchrotron science facility in Oxfordshire.

Diamond Light Source

Developing Excellence in Leadership, Training and Science Initiative (DELTAS), a collaboration with the (DFID) to establish cutting-edge research and training programmes across the African continent.

Department for International Development

The , a fast-tracked research programme with the goal of identifying clinical and public health interventions to counter the West African Ebola Epidemic.

Ebola Emergency Initiative

The Juvenile Diabetes Research Foundation/ Wellcome Trust facilitates research into the genetic component of type 1 diabetes and is based in the Cambridge Institute for Medical Research.

Diabetes and Inflammation Laboratory

The .

Seeding Drug Discovery Initiative

The , an international organisation focussing on three-dimensional structures of proteins of medical relevance with an emphasis on open data.

Structural Genomics Consortium

The , a non-profit, British genomics and genetics research institute.[15]

Wellcome Trust Sanger Institute

Investments[edit]

In August 2014, the Wellcome Trust bought the Co-operative Group's farm business (renamed Farmcare) for £249 million. This comprised "15,997 hectares (39,533 acres) of freehold and third party owned land, 15 farms, including three pack houses, over 100 residential properties, and 27 commercial properties."[35]


In 2015, the trust bought the Premier Marinas group.[36]

Criticisms[edit]

It has been reported that the Wellcome Trust has billions of investments in companies related to the problems the philanthropy wants to solve.[37] In the context of the COVID-19 pandemic, the trust has investments in pharmaceutical companies involved in the development and delivery of treatments for COVID-19, which means it has the potential to gain financially where those treatments are monetised.[38]

Peter Williams, 1967–1991

1991–1998

Bridget Ogilvie

Mike Dexter, 1998–2003

2003–2013

Mark Walport

2013–2023

Jeremy Farrar

Heads of International Research Organizations

List of wealthiest charitable foundations

Official website

Wellcome Trust Case Control Consortium (WTCCC)

Other Wellcome Trust websites

Scientific Conferences supported by the Wellcome Trust

Ex Memoria – Wellcome Trust Awarded Film

a Wellcome Collection collaboration with Channel 4

Surgery Live

European Society for Clinical Microbioloy and Infectious Diseases

Federation of European Biochemical Societies

European Federation of Pharmaceutical Societies

International Society for Infectious Diseases